KLK3 is widely used as a PSA in the clinic23, and KLK4 and KLK5 are involved in the treatment and prognosis of other cancers, such as ovarian cancers 24, triple-negative breast cancers (TNBC)25 and colorectal cancers (CRC)26. This evidence concerns the gene KLK4 and triple-negative breast carcinoma.